Overview

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

Status:
Recruiting

Trial end date:
2022-07-12

Target enrollment:

Participant gender:

Summary

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome

Phase:

Phase 3

Details

Lead Sponsor:

Allergan